| Journal | Cancer causes & control : CCC |
| Study Type | Clinical Study |
| Population | Human participants |
This nationally representative survey provides the first comprehensive epidemiologic data on cannabis and psychedelic use patterns among older cancer survivors, establishing baseline prevalence rates that inform clinical conversations and policy discussions. Understanding these usage patterns is essential as both substance categories gain therapeutic legitimacy for cancer-related symptoms.
This cross-sectional analysis of NSDUH data examined 63,959 U.S. adults aged ≥50 years, comparing lifetime cannabis and classic psychedelic use between cancer survivors and cancer-free individuals. Cannabis use prevalence was statistically equivalent between groups (41.6% vs 42.6%), while classic psychedelic use (LSD, psilocybin, peyote/mescaline) was modestly lower among cancer survivors. The study provides important epidemiologic context but cannot establish causality or therapeutic intent, and relies on self-reported lifetime use rather than current or medical use patterns.
“I find these prevalence rates remarkably high and clinically relevant—over 40% lifetime cannabis use in this older demographic suggests widespread familiarity that facilitates therapeutic discussions. The lower psychedelic rates among survivors likely reflect generational and medical caution rather than contraindication.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- Do cancer survivors use cannabis more frequently than individuals without cancer?
- Are cancer survivors more likely to use psychedelics like LSD or psilocybin?
- Should clinicians screen cancer survivors for substance use differently than other patients?
- Does cannabis or psychedelic use vary by cancer type among survivors?
- What are the clinical implications of co-use of cannabis and psychedelics among cancer survivors?
FAQ
Do cancer survivors use cannabis more frequently than individuals without cancer?
No, this large national survey found that cannabis use rates among cancer survivors aged 50 and older (41.6%) were similar to those without cancer (42.6%). This suggests that while cannabis may be used for symptom management, it’s not uniquely prevalent in the cancer survivor population compared to age-matched controls.
Are cancer survivors more likely to use psychedelics like LSD or psilocybin?
Actually, cancer survivors were less likely to report lifetime use of classic psychedelics. LSD use was 8.9% among survivors versus 10.3% in non-cancer individuals, and psilocybin use was 6.4% versus 7.7% respectively. This may reflect different risk tolerance or access patterns in this population.
Should clinicians screen cancer survivors for substance use differently than other patients?
Given the similar prevalence rates, standard substance use screening protocols appear appropriate for cancer survivors. However, clinicians should be aware that over 40% of survivors aged 50+ report lifetime cannabis use, making it important to discuss potential interactions with cancer treatments and ongoing medications.
Does cannabis or psychedelic use vary by cancer type among survivors?
The study indicates that subgroup analyses by cancer type/site were conducted, suggesting there may be variations in use patterns depending on the specific cancer diagnosis. However, the summary provided doesn’t detail these differences, which would require reviewing the full study results for clinical decision-making.
What are the clinical implications of co-use of cannabis and psychedelics among cancer survivors?
The study examined co-use patterns, which is clinically relevant given potential drug interactions and cumulative effects on cognition and treatment adherence. Healthcare providers should inquire about concurrent use of multiple substances when assessing cancer survivors, particularly given the complex medication regimens often required in this population.
